Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 11, 2024 08:00 ET | Source: BioVie, Inc.

BioVie Announces Pipeline Update and Near-Term Clinical Priorities

Recently completed financing provides sufficient funds for near-term Parkinson’s Disease priority Plans for Phase 2b trial of NE3107 as first-line monotherapy for Parkinson’s Disease being...
March 06, 2024 17:00 ET | Source: BioVie, Inc.

BioVie Inc. Announces Closing of Public Offering

CARSON CITY, Nev., March 06, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic...
March 04, 2024 01:32 ET | Source: BioVie, Inc.

BioVie Inc. Announces Pricing of Public Offering

CARSON CITY, Nev., March 04, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic...
March 01, 2024 16:58 ET | Source: BioVie, Inc.

BioVie Inc. Announces Proposed Public Offering of Common Stock

CARSON CITY, Nev., March 01, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of...
March 01, 2024 08:00 ET | Source: BioVie, Inc.

BioVie’s NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s Disease Patients and May Be Realigning Physiological Processes for Alzheimer’s Patients in Data to be Presented at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024

Data from Phase 2a trial in Parkinson’s Disease suggest patients treated with NE3107 experienced significant improvements in non-motor symptoms and motor control while placebo-treated patients...
February 06, 2024 08:00 ET | Source: BioVie, Inc.

BioVie to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

CARSON CITY, Nev., Feb. 06, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of...
November 29, 2023 08:00 ET | Source: BioVie, Inc.

BioVie Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer’s Disease

Positive Trending Data from 57 Per-Protocol Patients Suggest NE3107 is Biologically Active and May Have Impact on Cognitive, Functional, and Biomarker Endpoints Sponsor Identified Issues Relating to...
November 13, 2023 08:00 ET | Source: BioVie, Inc.

BioVie Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2023

Data Show that BIV201 in Combination with Standard of Care (SOC) is Well Tolerated with No Major Difference in Treatment-Emergent Adverse Events (TEAEs) Compared to SOC Alone With a ~50% Mortality...
November 02, 2023 08:00 ET | Source: BioVie, Inc.

BioVie to Participate in the Truist Securities BioPharma Symposium

CARSON CITY, Nev., Nov. 02, 2023 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of...
October 30, 2023 08:00 ET | Source: BioVie, Inc.

BioVie to Host Conference Call and Webcast Wednesday November 1, 2023 at 8:00 AM ET

CARSON CITY, Nev., Oct. 30, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of...